Table 2 Characteristics of the largest primary tumor (PT1) and second primary tumor (PT2) assessed with immunohistochemistry for patients with ipsilateral multifocal primary breast cancer
PT1 | PT21 | |
|---|---|---|
Tumor size, mm (median (IQR) | 22.0 (14–30) | 10.0 (7–15) |
Pathologic tumor size | ||
pT1 | 77 (42.1) | 153 (83.6) |
pT2 | 100 (54.6) | 30 (16.4) |
pT3 | 6 (3.3) | 0 (0.0) |
Histological grade, NHG | ||
1 | 36 (19.7) | 51 (27.9) |
2 | 111 (60.7) | 106 (57.9) |
3 | 36 (19.7) | 26 (14.2) |
Histological type | ||
Ductal | 125 (68.3) | 127 (69.4) |
Lobular | 22 (12.0) | 24 (13.1) |
Tubular | 15 (8.2) | 20 (10.9) |
Tubulolobular | 7 (3.8) | 7 (3.8) |
Mixed ductal and lobular | 12 (6.6) | 3 (1.6) |
Other | 2 (1.1) | 2 (1.1) |
ER | ||
Positive | 171 (93.4) | 172 (94.0) |
Negative | 12 (6.6) | 11 (6.0) |
PR | ||
Positive | 145 (80.9) | 146 (79.8) |
Negative | 38 (19.1) | 37 (20.2) |
Ki67 | ||
Low | 129 (70.5) | 146 (79.8) |
High | 54 (29.5) | 37 (20.2) |
HER2 | ||
Positive | 18 (9.8) | 18 (9.8) |
Negative | 165 (90.2) | 165 (90.2) |
Subtype | ||
Luminal A | 117 (63.9) | 129 (70.5) |
Luminal B HER2- | 40 (21.9) | 29 (15.8) |
Luminal B HER2 + | 14 (7.7) | 14 (7.7) |
Non-luminal HER2 + | 4 (2.2) | 4 (2.2) |
Triple-negative | 8 (4.4) | 7 (3.8) |